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Background: Newborn infants with respiratory failure are often treated with intubation and mechanical ventilation
for prolonged periods of time. Our objective was to evaluate whether increasing use of non-invasive respiratory support
in newborn infants can improve patient health and reduce costs.
Methods: We utilized a natural experiment that took place in October 2008 when a large neonatal intensive care unit
in Norway moved into a new hospital building with new medical equipment. A change in respiratory support towards
increasing use of nasal biphasic positive airway pressure (n-BiPAP) instead of invasive mechanical ventilation treatment
followed the acquisition of the new equipment. We used a difference-in-difference method and data from the Norwegian
National Patient Registry to assess morbidity, mortality, number of hospital days and hospital costs in our unit following
this change. We stratified the results according to gestational age groups.
Results: We found a reduction in morbidity including bronchopulmonary dysplasia, retinopathy of prematurity
and intraventricular hemorrhage. No change in mortality was found. We found a reduction in number of hospital
days and hospital costs for preterm infants with gestational age <28 weeks and for term infants with diagnoses
affecting respiration.
Conclusions: We conclude that increasing use of n-BiPAP may improve health and reduce costs. However, more
research is needed to establish best practice. Comparing hospitals where treatment practices change to hospitals
where the same change does not occur may be a useful way to evaluate the efficacy of such a change, especially
when hospitals can be studied over time.Background
Newborn infants with respiratory failure are often treated
with intubation and mechanical ventilation for prolonged
periods of time. In this study, we evaluated health out-
comes of patients and hospital costs associated with an
increasing use of nasal biphasic positive airway pressure
(n-BiPAP) instead of mechanical ventilation treatment
as the mode of respiratory support in term and preterm
infants with respiratory failure. We hypothesized that
increasing the use of n-BiPAP reduced morbidity and* Correspondence: Inger.Cathrine.Kann@ahus.no
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article, unless otherwise stated.mortality as well as the number of hospital days and
costs.
In newborn infants, mechanical ventilation through an
endotracheal tube is associated with both short- and long-
term complications [1]. On the other hand, non-invasive
respiratory support has been demonstrated to be less
injurious [2]. Early nasal continuous positive airway
pressure (n-CPAP) can reduce exposure to or duration
of mechanical ventilation in extremely preterm infants
[3] by, for instance, reducing the risk of extubation failure
[4]. N-BiPAP is another mode of non-invasive respiratory
support that may additionally reduce the need for mech-
anical ventilation [5,6] and complications like broncho-
pulmonary dysplasia (BPD), retinopathy of prematurity
(ROP), intraventricular hemorrhage (IVH), periventricularntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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which have been associated with mechanical ventilation
treatment in preterm infants.
In October 2008 Akershus University Hospital (Ahus)
in Norway moved into a new hospital building and the
new neonatal intensive care unit (NICU) acquired new
equipment for non-invasive respiratory support. These
machines allow for both n-CPAP and n-BiPAP treatment
and had not been used in more than a few other hospitals
in Norway at the time. Based on emerging knowledge that
n-BiPAP improved gas exchange compared to n-CPAP [7],
we started to use n-BiPAP, primarily in preterm infants with
inadequate oxygenation and/or ventilation on n-CPAP. We
also used n-BiPAP in term or near-term infants with re-
spiratory symptoms of any cause that experienced n-CPAP
failure. We utilized a treatment protocol similar to those
published for nasal intermittent positive pressure ventila-
tion (NIPPV) with short inflation times of 0.3-0.4 s and
high rates of 40–60 per minute. However, since our equip-
ment only allows for maximum pressures of 9–10 cm H2O,
we called this mode of respiratory support n-BiPAP, even
though higher inflation times (or time high [Thigh]) and
lower rates are more commonly used in this treatment mo-
dality. We assumed that other hospitals that did not utilize
n-BiPAP would have to intubate and mechanically ventilate
newborn infants that did not respond properly to n-CPAP
treatment, whether n-CPAP was used as primary treatment
or post-extubation.
To make causal inference, on what medical treatment
is most efficient and improves health most, is a challenge.
The most common method is randomized controlled trials
(RCTs) that select patients randomly to different treatment
methods. We instead utilized the change in treatment
practices that took place when Ahus moved into a new
hospital building and the change in respiratory support
towards increasing use of n-BiPAP instead of invasive
mechanical ventilation treatment that followed.
This change in treatment practices may be seen as a nat-
ural experiment. Such a quasi-experimental design has a
long tradition in social sciences [8,9], but we argue that
such methods could also be utilized in medicine where
RCTs are the gold standard for comparing treatments,
medical equipment, new technology or treatment modes.
In Norway, the provision of health care is organized
through health enterprises that are owned and governed by
the state regional health authorities. The regional health
authorities are financed by a combination of block grants
and an activity-based system. Together, the two types of
funding are meant to cover the running costs of providing
somatic hospital services. The government determines the
relative shares of the two sources of funding on a yearly
basis. The activity-based share is based on the Diagnosis-
Related Group (DRG) system and accounted for 40–60%
of the funding in the observation period. The DRG systemis meant to reflect the average costs of providing treatment
to patients within different DRGs [10]. One patient can
be categorized to several combined DRGs, depending on
treatment procedures. As DRG is based on an estimated
cost of a certain patient group, reducing expenditures, by
for instance reducing length of stay, for this patient group
will improve hospital economy, at least in the short term.
Infants on mechanical ventilator treatment often require
sedation and analgesia, arterial and central intravenous
lines, antibiotics and parenteral nutrition. Mechanical ven-
tilation may thus be expensive compared to n-BiPAP due
to the need for more intensive monitoring and care.
Increased use of n-BiPAP may therefore reduce hospital
costs as well as the number of hospital days (NHD). These
economic effects might be enhanced by reduced short-
and long-term morbidity in patients receiving n-BiPAP in-
stead of mechanical ventilation.
Methods
Ideally, in order to capture the effects of a change in treat-
ment procedures, we should know what the outcomes for
the exposed patients would have been in the original treat-
ment regime. Since this cannot be observed, the outcomes
for patients treated in hospitals that did not use n-BiPAP
represent the counterfactual.
We used a difference-in-difference (DID) approach [11].
Having data from 2002 to 2010, we were able to observe
outcomes in exposed and unexposed hospitals before, and
after, the change towards increasing use of n-BiPAP. This
allows us to control for the possibility that both groups
have changed over time for reasons unrelated to the inter-
vention or that they were different in some aspects at
baseline. In effect, the analysis isolates the impact of the
intervention by removing other known or unknown fac-
tors that may have affected the groups during the study
period.
The DID design is based on comparing four different
groups. Three of these groups are not affected by the in-
vestigated treatment, which in this study was n-BiBAP.
The difference between Ahus before November 1st 2008
(a) and after October 31st 2008 (b) compared to the differ-
ence between the unexposed hospitals before November
1st (c) and after October 31st 2008 (d) was calculated. The
DID unadjusted is: (b-a)-(d-c). Thus, if the exposed and
unexposed are subject to the same time trends, such as
changes in medication practices like the use of antenatal
steroids and surfactant treatment, this will not confound
the results, since we use the change in the other hospitals
as a reference.
No other changes in the treatment protocols of sick
term and preterm infants took place at Ahus at the same
time. There were no big changes in the care of the infants’
mothers prior to birth such as the use of antenatal steroids,
other than the national trends. There has been a move
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the last decade, unrelated to the use of n-BiPAP. However,
since we in the DID approach use the trends in other hospi-
tals as reference, such trends will not confound the results.
We performed regression analyses using individual data;
adjusted for compositional differences in the patient popu-
lations by including gender, birth weight, and patent ductus
arteriosus (PDA); and took into account whether or not
the admission was planned. In Norway, a planned hospital
admission of an infant the first year of life is usually due to
a transfer for a procedure or treatment at a tertiary referral
center and then back to the referring hospital. All other ad-
missions the first year of life, including the admission to
the NICU at birth, are defined as unplanned and may indi-
cate differences in health status of the individuals included
in the study.
All outcome parameters were analyzed within the DID
framework. However, the outcome parameters were in dif-
ferent formats, and thus, different regressions were used.
For the linear outcome parameters; NHD and hospital costs
(DRGs), an ordinary least-square regression was used.
However, these variables all demonstrated a skewed dis-
tribution. Thus, a log transformation was also performed.
An ordinary least-square regression on log-transformed
data has often been used in this kind of data and appears
to be a consistently performing estimator [12]. Regarding
the outcome of mortality, we had the date of death and
thus a Cox regression was used to estimate the effect
on mortality. Logistic regressions were used for the other
health outcomes. Regression results are presented with
95% confidence intervals (CI). All analyses were conducted
in Stata, version 12 (StataCorp LP, Texas, USA).
We used individual data from the Norwegian Patient
Register (NPR) 2002–2010.
For each patient, we have information on NHD, gender,
DRG, diagnoses, and treatment procedures, whether or not
the admission was planned, in which hospital the treat-
ment was performed and the date of death recorded if the
patient died in the hospital. For all patients, we included
diagnoses and treatment procedures per patient, per year
and per hospital, regardless whether they were primary
or secondary diagnoses or procedures. This is important,
since what is reported as primary diagnoses may be a stra-
tegic choice of hospitals according to DRG rates [13].
The main outcome parameters for the preterm infants
were morbidity, defined as BPD, ROP, IVH, PVL and/or
NEC and in-hospital mortality; as well as NHD, defined as
the number of hospital days per patient within the same
year and hospital; and hospital costs within the same year
and hospital, measured in aggregated DRGs per patient.
For term infants, the outcomes were only NHD and hos-
pital costs (DRGs).
We included only hospitals certified to care for preterm
infants with gestational age (GA) <28 weeks, by which weattempted to reduce heterogeneity. We excluded other
hospitals that started to utilize n-BiPAP during the obser-
vation period. These hospitals could have been included in
the treatment (exposed) group. However, as indications
for and extent of use of n-BiPAP varied among exposed
hospitals, and the exact date when n-BiPAP was intro-
duced as a treatment modality in these hospitals could not
be established, we decided to exclude them from the main
analysis.
We defined an infant as being born the same year he or
she was admitted to the hospital. Our unit of observation
was preterm infants as well as term infants with diagnoses
affecting respiration by hospital and year. Diagnoses that
frequently affect respiration and cause a need for respira-
tory support include ‘respiratory failure’, respiratory distress
syndrome, persistent pulmonary hypertension, transitory
tachypnoe of the newborn/wet lung, meconium aspiration
syndrome and perinatal asphyxia.
The NPR assigned patients with a new identification
(ID) number each year, and in each hospital, the patients
were admitted before 2008. After 2008, the NPR allows for
tracking individual patients between years and hospitals. In
order to make data after 2008 comparable with those be-
fore 2008, we gave each patient a new ID for each year and
hospital. We stratified the data according to the gestational
age groups extremely preterm infants (GA <28 weeks),
other preterm infants (GA ≥28 but <37 weeks), and term
infants with respiratory symptoms (Figure 1).
By coincidence, three out of six infants who died at Ahus
in 2010 had trisomy 18. Hence, we excluded all infants
(13 preterm and 18 term infants) with this severe chromo-
somal abnormality that is associated with high mortality
and morbidity but cannot be improved by the new treat-
ment procedure.
In Norway, pregnant women can choose which hospital
to give birth in, which in general is the hospital closest to
their home. The exception is an anticipated very preterm
birth which is regarded as an emergency, and the woman
will deliver in the most nearby hospital, unless she is
expected to give birth prior to gestational week 26. Caring
for infants younger than 26 weeks of gestation is a central-
ized task, as is cardiac anomalies or other severe malforma-
tions diagnosed in the fetus. We allowed for an individual
hospital effect by a dummy per hospital due to some of the
resulting differences in the patient population between
hospitals.
Ethics statement
The research has been performed in accordance with the
Declaration of Helsinki. We used data from the Norwegian
patient registry (NPR). This is a registry including all
patients treated in all Norwegian hospitals. The data
were processed in accordance with guidelines issued
by the Local Privacy Legislation Authority, and results
Figure 1 Flow chart describing the study population. *’Respiratory symptoms’ include the diagnoses respiratory failure, respiratory distress
syndrome, persistent pulmonary hypertension, transitory tachypnoe of the newborn/wet lung, meconium aspiration syndrome and perinatal
asphyxia.
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anonymity. Using data from NPR was approved by The
Norwegian Data Protection Authority, reference- 11/00266-
4/CGN. Individual consent was not required as we utilized
data from NPR and the natural experiment that took place
when Ahus moved into a new hospital buildings and the
change in respiratory support that followed. All infants in all
Norwegian hospitals were treated according to best practice
and guidelines available at the time. This study is an assess-
ment of minor differences in treatment practices. Such qual-
ity assessments were one of the political motivations
for establishing NPR registry.
Results
Table 1 compares the outcome variables, for the four
groups Ahus before November 1st 2008 (a) and Ahus
after October 31st 2008 (b) compared to the unexposed
before November 1st 2008 (c) and after October 31st 2008
(d), stratified by the three gestational age groups. On
average, treatment costs for extremely preterm infants
(GA <28 weeks) at Ahus were reduced from 10.7 to 6.7
DRGs, while we observed a slight increase from 13.0 to
13.8 in other hospitals during the same period. The un-
adjusted DID is (6.7-10.7)-(13.8-13.0) = −4.7 DRGs. Thus,
the change in Ahus is measured using the change in other
hospitals as reference. A reduction by 4.7 DRGs, represents
approximately 22,000 EUR per patient. The extremelypreterm infants spent on average 47 days in hospital be-
fore Ahus moved into a new hospital building and 18 days
after, while other hospitals changed from 37 to 34 days, i.e.
an unadjusted effect of (47–18)-(37–34) =26 days. NHD
in term infants with diagnoses affecting respiration chan-
ged from 8.4 to 4.9 days at Ahus and from 7.3 to 6.9 in the
other hospitals, thus the unadjusted effect is 3.1 days for
term infants with respiratory problems.
Table 2 displays the results from the logistic regression
and the Cox regression. We found a reduced morbidity
by approximately 60% in the exposed population at Ahus
for both extremely preterm and other preterm infants when
adjusting for confounding variables, No change in mortality
after the introduction of n-BiPAP treatment was found.
Table 3 displays the results from the ordinary least-square
regression. For the extremely preterm infants, we found a
reduction in NHD by 70% at Ahus after October 31st 2008,
or 26 days on average. Costs measured by DRG points
were also reduced by 67% (Table 3). For this patient
group, this represents (≈26 patients per year)*60.000
(average cost per patient)*48% ≈ 212,655 EUR (95% CI
107,092 EUR −1,483,995 EUR) saved per year at Ahus.
For term infants, we found a reduction in NHD days by
75%, or 1–5 days. The costs measured by DRG points were
reduced by 67% or by 0.6 to 1.8 points. For this patient
group, this represents (≈250 patients per year)*9.000
(average cost per patient)*33% ≈ 1,521,524 EUR (95% CI
Table 1 Descriptive statistics, before and after the introduction of n-BiPAP treatment at Ahus stratified by gestational
age groups
Ahus before November
1st 2008 (a)
Ahus after October
31st 2008 (b)
All hospitals but Ahus before
November 1st 2008 (c)
All hospitals but Ahus after
October 31st 2008 (d)
Difference in
difference (b-a)-(d-c)
Preterm infants <28 weeks (N =989)
Fraction Fraction Fraction Fraction (b-a)-(d-c)
BPD 0.313 0.094 0.243 0.116 −0.091
ROP 0.063 0.000 0.106 0.184 −0.141
IVH 0.063 0.038 0.244 0.168 0.051
Combined
morbidity
0.375 0.151 0.502 0.421 −0.144
In-hospital
death
0.107 0.075 0.268 0.221 0.015
Mean Mean Mean Mean (b-a)-(d-c)
NHD 47.964 18.585 37.282 34.116 −26.213
DRG 10.729 6.709 13.066 13.842 −4.796
N 112 53 634 190
Preterm infants 28–37 weeks (N =13209)
Fraction Fraction Fraction Fraction (b-a)-(d-c)
BPD 0.023 0.006 0.016 0.009 −0.010
ROP 0.004 0.006 0.013 0.025 −0.010
IVH 0.010 0.006 0.019 0.016 −0.001
Combined
morbidity
0.032 0.017 0.044 0.046 −0.018
In hospital
death
0.004 0.009 0.015 0.014 0.006
Mean Mean Mean Mean (b-a)-(d-c)
NHD 17.246 16.494 15.573 15.175 −0.354
DRG 4.939 5.130 5.097 5.609 −0.321
N 1680 538 8290 2701
Term infants with respiratory symptoms (N =10270):
Mean Mean Mean Mean (b-a)-(d-c)
NHD 8.433 4.913 7.332 6.916 −3.104
DRG 2.009 1.431 1.767 2.253 −1.064
N 1082 482 6646 2060
Patent ductus arteriousus (PDA), Bronchopulmonary dysplasia (BPD), Retinopathy of prematurity (ROP), Intraventricular hemorrhage (IVH), Number of hospital days
(NHD), Nasal biphasic positive airway pressure (n-BiPAP), Akershus University Hospital (Ahus).
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We found no change in NHD or DRG for other preterm
infants.
Complications of prematurity and other complications
in the perinatal period can lead to major disability like
cerebral palsy in the survivors. The long-term costs of
patients with, for instance, BPD, ROP and cerebral palsy
resulting from IVH can be great. However, as there is no
precise way to quantify such costs, we chose to extrapo-
late by using compensations received by plaintiffs that
have suffered from medical malpractice in the perinatal
period. In Norway, such reimbursement for cerebral palsy
caused by IVH has in recent years been approximately400,000 EUR per child with a severe disability. Severe ROP
was reimbursed by 1,000,000 EUR in one severe case.
Having one or more of the morbidities and assuming a
reduction by ≈ 60% (Table 2), this represents approximately
10 patients per year at Ahus, i.e., 2,400,000-6,000,000 EUR
saved in costs associated with long-term disability at Ahus
per year.
The cost related to a change in mode of treatment simi-
lar to the one made at Ahus are only investment costs,
since costs associated with the education of staff in the
new mode of assisted ventilation are minimal. All hospitals
will still need equipment related to mechanical ventilation
assistance, i.e., business as usual will have no change in
Table 2 Estimated effect on health outcomes, stratified by gestational age
Logistic regression Cox regression
Odds ratio Odds ratio Odds ratio Odds ratio Hasard ratio
ROP BPD IVH Morbidity Mortality
Preterm infants <28 weeks (N =989)
DID-estimate . 0.350*** 0.674 0.393*** 1.945
95% CI . [0.305,0.402] [0.202,2.247] [0.287,0.540] [0.217,17.409]
Preterm infants 28–37 weeks (N =13209)
DID-estimate 1.392 0.243*** 0.397*** 0.397*** 2.143
95% CI [0.747,2.595] [0.200,0.295] [0.321,0.492] [0.337,0.468] [0.335,13.697]
The results are adjusted for weight, gender, PDA and whether or not the admission was planned.
***p <0.001.
Bronchopulmonary dysplasia (BPD), Retinopathy of prematurity (ROP), Intraventricular hemorrhage (IVH), Difference-in-difference (DID), Confidence interval (CI). No
observations of ROP at Ahus after the intervention, a change cannot be estimated.
Kann and Solevåg BMC Health Services Research 2014, 14:494 Page 6 of 8
http://www.biomedcentral.com/1472-6963/14/494investment. Ahus has purchased nine machines, which
the staff evaluated as a sufficient number. If we assume
that they can be used in 10 years, the yearly cost for Ahus
is approximately 100,000 EUR per year. Accordingly, the
savings far exceed the costs, even at the lowest estimates
of savings.
Discussion
In this study, we found that morbidity and number of hos-
pital days and hospital costs were significantly reduced fol-
lowing a change toward an increasing use of non-invasive
respiratory support for preterm infants. For term infants,
we found a reduction in NHD and hospital costs. The
need for invasive mechanical ventilation may have beenTable 3 Estimated effect on costs and number of hospital day
Ordinary least square regression
Log transformed
Number of hospital days DRG poin
Preterm infants <28 weeks (N =989):
DID-estimate −0.861* −0.482*
95% CI [−1.565,-0.157] [−0.931,-0.
N 989 989
R-sq 0.076 0.095
Preterm infants 28–37 weeks (N =13209):
DID-estimate −0.05 0.017
95% CI [−0.242,0.142] [−0.078,0.1
N 13209 13209
R-sq 0.322 0.206
Term infants - with respiratory problems (N =10270):
DID-estimate −0.257** −0.326***
[−0.443,-0.0705] [−0.443,-0.
N 10270 10270
R-sq 0.07 0.172
The results are adjusted for weight, gender, patent ductus arteriosus and whether o
*p <0.05, **p <0.01, ***p <0.001, confidence intervals in brackets.
Difference-in-difference (DID), Confidence interval (CI).reduced, as well as the need for staff due to easier surveil-
lance and shorter hospital stays in the initial treatment of
the newborn infant.
Using changes in treatment practices or investments in
one hospital that does not happen in other hospitals at the
same time may be a way of evaluating procedural and
technological changes as long as we have data on out-
comes both before and after the change for both the
exposed and unexposed hospitals. In this way, we can esti-
mate opportunities for improved health, reduced costs,
and/or increased efficiency while the changes are used in a
normal hospital setting.
Some patients may have a prolonged stay in local hospi-
tals following discharge from the study hospitals. However,s, stratified by gestational age
Ordinary least square regression
ts Number of hospital days DRG points
−26.60* −5.428***
0326] [−47.46,-5.738] [−8.344,-2.513]
989 989
0.076 0.115
−1.656 −0.266
13] [−4.839,1.527] [−0.787,0.254]
13209 13209
0.327 0.323
−3.023** −1.288***
209] [−5.113,-0.933] [−1.897,-0.680]
10270 10270
0.078 0.21
r not the admission was planned.
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NICUs and almost invariably discharges infants to their
home. NHD at Ahus therefore most often reflects the total
length of hospital stay in the neonatal period, and the re-
duction of NHD at Ahus after October 31st 2008 is not
likely to be associated with prolonged stays in other units.
However, the NPR does not have information about this,
since it does not allow for following patients between hos-
pitals over the entire study period. In Norway, delivery
and treatment of extremely premature infants are central-
ized tasks. Once infants are stabilized, often synonymous
with being off mechanical ventilation, they are transferred
to hospitals closer to home. Hence, in general, a reduction
in ventilator days would allow for an earlier transfer to
local hospitals and additional benefits for patients, neo-
natal service provision and for families.
The regression does not indicate changed mortality,
though the estimates are based on few observations. In
the patient group with highest mortality, i.e. the patients
born before 28 weeks of gestation, no increase in mortality
was seen. However, early mortality with a non-invasive
treatment method needs more research and should be
followed closely.
Using large population registers for evaluating changes
in treatment procedures that occur in one unit is import-
ant regarding the costs associated with registry administra-
tion. Many countries cannot afford managing such a total
patient registry. Norway has chosen to prioritize gathering
data on all patients admitted to hospital since 1997. It is
important to use such registers in research also in order to
improve the quality of registration and coding practices.
Limitations of the study include its retrospective nature.
Changes other than n-BiPAP may have occurred at Ahus
only and at the time when Ahus moved into a new hospital
building. Even though we controlled for some confounding
variables, we cannot conclude that the observed changes
were due to the new treatment procedures under investiga-
tion. Moving into new hospital buildings may have affected
our patient group in ways for which we did not account.
Renewal of all medical equipment, besides the n-CPAP/
n-BiPAP machines, is likely to have improved efficiency
and quality of care. However, the move was not associated
with significant changes in staff or other medical guidelines.
Thus to check the robustness of the results, we per-
formed the regression including the other exposed hos-
pitals that we excluded from our main analyses. In this
analysis we excluded Ahus. With this alternative regres-
sion, we found similar effects on morbidity and hospital
costs, and most health outcomes for extremely preterm
infants. This strengthens our results. However, the alterna-
tive regression indicated increased mortality among the
smallest babies. The protocols for n-BiPAP usage in differ-
ent units may play a role in mortality, and further studies
are required. We did not include these units in the mainstudy, because we only knew the month of purchase of
the equipment that allowed for n-BiPAP treatment. We
did not know if, when or on what indications the n-BiPAP
treatment was used. However, including these units has an
advantage, since the different units bought the equipment
at different times, which makes the regression results
more robust.
The NPR did not allow us to follow individual patients
as they were transferred between hospitals and units. This
makes us unable to make conclusions about the total length
of hospital stay for each infant. However, the NHD in our
unit was significantly reduced after we started to treat
infants with n-BiPAP. As our unit is not a tertiary referral
center, we almost exclusively treat infants that belong to
our own referral area. As previously mentioned, very few
patients are transferred to other units after discharge from
our NICU. Hence, the possibility that a shorter stay in our
NICU is followed by a longer stay in another unit is
unlikely.
There has been a move towards less mechanical ventila-
tion in newborns in general the last decade, unrelated to
the use of n-BiPAP. However, the DID approach will en-
sure that this will not confound the results. It is likely that
Ahus has followed national guidelines concerning these
treatments. If the levels of antenatal steroids and surfac-
tant treatment, are different in various hospitals, or if they
change over time, this will not confound the results. This
is resolved using the DID approach.
There has been no other major change in the care of
preterm infants the last decade comparable to antenatal
steroids and surfactant treatment of respiratory distress
syndrome 20 years ago. However, if there had been changes
in such use, it would only confound our results if it hap-
pened at Ahus only, and at the same time as Ahus moved
into a new hospital building.Conclusions
In conclusion, assessing the effect of a shift towards n-
BiPAP instead of mechanical ventilation treatment of term
and preterm infants in need of respiratory support, by
using a population register, we found a reduction in mor-
bidity, the number of hospital days needed, and hospital
costs. The retrospective nature of the study offers chal-
lenges but also advantages. In prospective studies, report-
ing side effects and negative outcomes may be influenced
by the staff being aware that the treatment practices are
under evaluation, and we argue that population registers
and DID methods can be useful in estimating effects of
changes in treatment practices. A total population registry
has the potential of evaluating the health effects and costs
of investments within a DID framework, given that the in-
vestments are not introduced in all hospitals at the same
time.
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